Brief: Foghorn Therapeutics Provides Update On Fhd-286 Clinical Development Program

Foghorn Therapeutics

16/12/2024 12:29

Dec 16 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS PROVIDES UPDATE ON FHD-286 CLINICAL
DEVELOPMENT PROGRAM AND STRATEGIC PRIORITIES
    * FOGHORN THERAPEUTICS INC. - TO DISCONTINUE INDEPENDENT
DEVELOPMENT OF FHD-286 FOR AML
    * FOGHORN THERAPEUTICS INC. - EVALUATING PARTNERSHIPS AND
ISTS TO
ADVANCE FHD-286
    * FOGHORN THERAPEUTICS INC. - TO PRIORITIZE PROPRIETARY
PIPELINE
AND LILLY COLLABORATION PROGRAMS
    * FOGHORN THERAPEUTICS INC. - PHASE 1 TRIAL OF FHD-286
SHOWED
CLINICAL RESPONSES BUT DID NOT MEET THRESHOLD

Source text:  ID:nGNXXnDbx 
Further company coverage:  FHTX.O